切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2019, Vol. 08 ›› Issue (02) : 91 -95. doi: 10.3877/cma.j.issn.2095-3232.2019.02.003

专家论坛

纳米刀治疗原发性肝癌研究进展
戴子浩1, 廖俊彬1, 林满霞2, 彭穗3, 匡铭4,()   
  1. 1. 510080 广州,中山大学附属第一医院肝外科
    2. 510080 广州,中山大学附属第一医院介入超声科
    3. 510080 广州,中山大学附属第一医院临床研究中心
    4. 510080 广州,中山大学附属第一医院肝外科;510080 广州,中山大学附属第一医院介入超声科
  • 收稿日期:2018-12-03 出版日期:2019-04-10
  • 通信作者: 匡铭
  • 基金资助:
    广东省科技计划项目(2016A020215189); 广州市科技计划-民生科技项目(201704020099)

Recent research of irreversible electroporation for primary liver cancer

Zihao Dai1, Junbin Liao1, Manxia Lin2   

  • Received:2018-12-03 Published:2019-04-10
引用本文:

戴子浩, 廖俊彬, 林满霞, 彭穗, 匡铭. 纳米刀治疗原发性肝癌研究进展[J]. 中华肝脏外科手术学电子杂志, 2019, 08(02): 91-95.

Zihao Dai, Junbin Liao, Manxia Lin. Recent research of irreversible electroporation for primary liver cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2019, 08(02): 91-95.

[1]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[2]
中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版)[J].中华肝脏病杂志201725(12): 886-895.
[3]
Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314.
[4]
Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150(4):835-853.
[5]
Jiang C, Davalos RV, Bischof JC. A review of basic to clinical studies of irreversible electroporation therapy[J]. IEEE Trans Biomed Eng, 2015, 62(1):4-20.
[6]
Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation[J]. Ann Biomed Eng, 2005, 33(2):223-231.
[7]
Rubinsky B. Irreversible electroporation in medicine[J]. Technol Cancer Res Treat, 2007, 6(4):255-260.
[8]
Golberg A, Bruinsma BG, Uygun BE, et al. Tissue heterogeneity in structure and conductivity contribute to cell survival during irreversible electroporation ablation by "electric field sinks"[J]. Sci Rep, 2015(5):8485.
[9]
Frühling P, Nilsson A, Duraj F, et al. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: short to mid-term results[J]. Eur J Surg Oncol, 2017, 43(4):751-757.
[10]
Zimmerman A, Grand D, Charpentier KP. Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives[J].J Hepatocell Carcinoma, 2017(4):49-58.
[11]
Niessen C, Igl J, Pregler B, et al. Factors associated with short-term local recurrence of liver cancer after percutaneous ablation using irreversible electroporation: a prospective single-center study[J].J Vasc Interv Radiol, 2015, 26(5):694-702.
[12]
Herwald SE, Chen JH, Arellano RS. Irreversible electroporation for treatment of hepatocellular carcinoma adjacent to the gallbladder[J]. J Vasc Interv Radiol, 2016, 27(7):1093-1094.
[13]
Distelmaier M, Barabasch A, Heil P, et al. Midterm safety and efficacy of irreversible electroporation of malignant liver tumors located close to major portal or hepatic veins[J]. Radiology, 2017, 285(3):1023-1031.
[14]
Sutter O, Calvo J, N'Kontchou G, et al. Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: a retrospective single-center case series[J]. Radiology, 2017, 284(3):877-886.
[15]
Cheung W, Kavnoudias H, Roberts S, et al. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes[J]. Technol Cancer Res Treat, 2013, 12(3):233-241.
[16]
Faroja M, Ahmed M, Appelbaum L, et al. Irreversible electroporation ablation: is all the damage nonthermal?[J]. Radiology, 2013, 266(2):462-470.
[17]
Adeyanju OO, Al-Angari HM, Sahakian AV. The optimization of needle electrode number and placement for irreversible electroporation of hepatocellular carcinoma[J]. Radiol Oncol, 2012, 46(2):126-135.
[18]
Beyer LP, Pregler B, Michalik K, et al. Evaluation of a robotic system for irreversible electroporation (IRE) of malignant liver tumors: initial results[J]. Int J Comput Assist Radiol Surg, 2017, 12(5):803-809.
[19]
Beyer LP, Pregler B, Nießen C, et al. Stereotactically-navigated percutaneous Irreversible Electroporation (IRE) compared to conventional IRE: a prospective trial[J]. PeerJ, 2016(4):e2277.
[20]
Lee EW, Wong D, Prikhodko SV, et al. Electron microscopic demonstration and evaluation of irreversible electroporation-induced nanopores on hepatocyte membranes[J]. J Vasc Interv Radiol, 2012, 23(1):107-113.
[21]
Lee EW, Chen C, Prieto VE, et al. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation[J]. Radiology, 2010, 255(2):426-433.
[22]
朱统寅,孙军辉,陈新华,等.CT导引纳米刀消融猪肝脏可行性实验研究[J].介入放射学杂志201625(4):337-340.
[23]
Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation[J]. Technol Cancer Res Treat, 2005, 4(6):699-705.
[24]
Guo Y, Zhang Y, Klein R, et al. Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma[J]. Cancer Res, 2010, 70(4):1555-1563.
[25]
Onik G, Rubinsky B. Irreversible electroporation: first patient experience focal therapy of prostate cancer (irreversible electroporation)[M]. Berlin Heidelberg: Springer, 2010.
[26]
黄凯文.履险如夷之纳米刀肝癌消融[J/CD].肝癌电子杂志, 20152(2):36-41.
[27]
Bhutiani N, Philips P, Scoggins CR, et al. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC)[J]. HPB, 2016, 18(7):593-599.
[28]
Sugimoto K, Moriyasu F, Kobayashi Y, et al. Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan[J]. Jpn J Radiol, 2015, 33(7):424-432.
[29]
Zeng J, Liu G, Li ZH, et al. The safety and efficacy of irreversible electroporation for large hepatocellular carcinoma[J]. Technol Cancer Res Treat, 2017, 16(1):120-124.
[30]
Cheng RG, Bhattacharya R, Yeh MM, et al. Irreversible electroporation can effectively ablate hepatocellular carcinoma to complete pathologic necrosis[J]. J Vasc Interv Radiol, 2015, 26(8):1184-1188.
[31]
Llovet JM, Vilana R, Brú C, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma[J]. Hepatology, 2001, 33(5):1124-1129.
[32]
de Baère T, Risse O, Kuoch V, et al. Adverse events during radiofrequency treatment of 582 hepatic tumors[J]. AJR Am J Roentgenol, 2003, 181(3):695-700.
[33]
Stigliano R, Marelli L, Yu D, et al. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. what is the risk and the outcome? seeding risk for percutaneous approach of HCC[J]. Cancer Treat Rev, 2007, 33(5):437-447.
[34]
Wong SL, Mangu PB, Choti MA, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer[J]. J Clin Oncol, 2010, 28(3):493-508.
[35]
Livraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study[J]. Radiology, 2003, 226(2):441-451.
[36]
Chen X, Ren Z, Yin S, et al. The local liver ablation with pulsed electric field stimulate systemic immune reaction against hepatocellular carcinoma (HCC) with time-dependent cytokine profile[J]. Cytokine, 2017(93):44-50.
[37]
Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy[J]. Nat Rev Cancer, 2014, 14(3):199-208.
[38]
Li X, Xu K, Li W, et al. Immunologic response to tumor ablation with irreversible electroporation[J]. PLoS One, 2012, 7(11):e48749.
[39]
Neal RE 2nd, Rossmeisl JH Jr, Robertson JL, et al. Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice[J]. PLoS One, 2013, 8(5):e64559.
[40]
Bulvik BE, Rozenblum N, Gourevich S, et al. Irreversible electroporation versus radiofrequency ablation: a comparison of local and systemic effects in a small-animal model[J]. Radiology, 2016, 280(2):413-424.
[1] 韩丹, 王婷, 肖欢, 朱丽容, 陈镜宇, 唐毅. 超声造影与增强CT对儿童肝脏良恶性病变诊断价值的对比分析[J]. 中华医学超声杂志(电子版), 2023, 20(09): 939-944.
[2] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[3] 陈忠垚, 陈胜灯, 李秋. 不同手术时机对原发性肝癌自发破裂出血患者远期预后的影响[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 518-521.
[4] 孟令展, 朱震宇. 达芬奇机器人辅助肝中叶切除术[J]. 中华普外科手术学杂志(电子版), 2023, 17(04): 373-373.
[5] 杜锡林, 谭凯, 贺小军, 白亮亮, 赵瑶瑶. 肝细胞癌转化治疗方式[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 597-601.
[6] 唐灿, 李向阳, 秦浩然, 李婧, 王天云, 柯阳, 朱红. 原发性肝脏神经内分泌肿瘤单中心12例诊治与疗效分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 674-680.
[7] 崔佳琪, 吴迪, 陈海艳, 周惠敏, 顾元龙, 周光文, 杨军. TACE术后并发肝脓肿的临床诊治分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 688-693.
[8] 韩冰, 顾劲扬. 深度学习神经网络在肝癌诊疗中的研究及应用前景[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 480-485.
[9] 何传超, 肖治宇. 晚期肝癌综合治疗模式与策略[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 486-489.
[10] 王楚风, 蒋安. 原发性肝癌的分子诊断[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 499-503.
[11] 顾娇娇, 邹燕, 陈奕辰, 黄师菊, 张慧玲, 林楠. 基于简易营养评价精法评估肝癌患者出院后营养状况及其影响因素[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 534-539.
[12] 孟令展, 李虎, 俞鹏, 于燕宾, 曹李, 翟伟, 高远, 邵艳玲, 严锦, 朱震宇. ICG荧光染色在肝癌腹腔镜解剖性肝切除术中的应用[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 557-561.
[13] 赫嵘, 贾哲, 张珂, 李代京, 张萌, 蒋力. 基于PSM分析腹腔镜肝切除联合Hassab术治疗合并门静脉高压症肝癌疗效[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 376-383.
[14] 杨发才, 游川, 雷正清, 李伟男, 段安琪, 邱应和, 李敬东, 程张军. 肿瘤负荷评分联合淋巴结分期对肝内胆管细胞癌患者术后生存预测价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 389-394.
[15] 李映安, 晋云, 储心昀, 胡苹苹, 王峻峰. 混合现实技术在腹腔镜肝切除术中导航的应用[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 401-406.
阅读次数
全文


摘要